Renal deletion of 12 kDa FK506-binding protein attenuates tacrolimus-induced hypertension

Rebecca A. Lazelle, Belinda McCully, Andrew S. Terker, Nina Himmerkus, Katharina I. Blankenstein, Kerim Mutig, Markus Bleich, Sebastian Bachmann, Chao-Ling Yang, David Ellison

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Tacrolimus is a widely used immunosuppressive drug that inhibits the phosphatase calcineurin when bound to the 12 kDa FK506-binding protein (FKBP12). When this binding occurs in T cells, it leads to immunosuppression. Tacrolimus also causes side effects, however, such as hypertension and hyperkalemia. Previously, we reported that tacrolimus stimulates the renal thiazide-sensitive sodium chloride cotransporter (NCC), which is necessary for the development of hypertension. However, it was unclear if tacrolimus-induced hypertension resulted from tacrolimus effects in renal epithelial cells directly or in extrarenal tissues, and whether inhibition of calcineurin was required. To address these questions, we developed a mouse model in which FKBP12 could be deleted along the nephron. FKBP12 disruption alone did not cause phenotypic effects. When treated with tacrolimus, however, BP and the renal abundance of phosphorylated NCC were lower in mice lacking FKBP12 along the nephron than in control mice. Mice lacking FKBP12 along the nephron also maintained a normal relationship between plasma potassium levels and the abundance of phosphorylated NCC with tacrolimus treatment. In cultured cells, tacrolimus inhibited dephosphorylation of NCC. Together, these results suggest that tacrolimus causes hypertension predominantly by inhibiting calcineurin directly in cells expressing NCC, indicating thiazide diuretics may be particularly effective for lowering BP in tacrolimus-treated patients with hypertension.

Original languageEnglish (US)
Pages (from-to)1456-1464
Number of pages9
JournalJournal of the American Society of Nephrology
Volume27
Issue number5
DOIs
StatePublished - May 1 2016

Fingerprint

Tacrolimus Binding Proteins
Tacrolimus
Tacrolimus Binding Protein 1A
Hypertension
Kidney
Nephrons
Calcineurin
Member 3 Solute Carrier Family 12
Sodium Chloride Symporter Inhibitors
Hyperkalemia
Immunosuppressive Agents
Immunosuppression
Cultured Cells
Potassium
Epithelial Cells

ASJC Scopus subject areas

  • Nephrology

Cite this

Renal deletion of 12 kDa FK506-binding protein attenuates tacrolimus-induced hypertension. / Lazelle, Rebecca A.; McCully, Belinda; Terker, Andrew S.; Himmerkus, Nina; Blankenstein, Katharina I.; Mutig, Kerim; Bleich, Markus; Bachmann, Sebastian; Yang, Chao-Ling; Ellison, David.

In: Journal of the American Society of Nephrology, Vol. 27, No. 5, 01.05.2016, p. 1456-1464.

Research output: Contribution to journalArticle

Lazelle, Rebecca A. ; McCully, Belinda ; Terker, Andrew S. ; Himmerkus, Nina ; Blankenstein, Katharina I. ; Mutig, Kerim ; Bleich, Markus ; Bachmann, Sebastian ; Yang, Chao-Ling ; Ellison, David. / Renal deletion of 12 kDa FK506-binding protein attenuates tacrolimus-induced hypertension. In: Journal of the American Society of Nephrology. 2016 ; Vol. 27, No. 5. pp. 1456-1464.
@article{56dd80fad1934aebb1b62c46d2388998,
title = "Renal deletion of 12 kDa FK506-binding protein attenuates tacrolimus-induced hypertension",
abstract = "Tacrolimus is a widely used immunosuppressive drug that inhibits the phosphatase calcineurin when bound to the 12 kDa FK506-binding protein (FKBP12). When this binding occurs in T cells, it leads to immunosuppression. Tacrolimus also causes side effects, however, such as hypertension and hyperkalemia. Previously, we reported that tacrolimus stimulates the renal thiazide-sensitive sodium chloride cotransporter (NCC), which is necessary for the development of hypertension. However, it was unclear if tacrolimus-induced hypertension resulted from tacrolimus effects in renal epithelial cells directly or in extrarenal tissues, and whether inhibition of calcineurin was required. To address these questions, we developed a mouse model in which FKBP12 could be deleted along the nephron. FKBP12 disruption alone did not cause phenotypic effects. When treated with tacrolimus, however, BP and the renal abundance of phosphorylated NCC were lower in mice lacking FKBP12 along the nephron than in control mice. Mice lacking FKBP12 along the nephron also maintained a normal relationship between plasma potassium levels and the abundance of phosphorylated NCC with tacrolimus treatment. In cultured cells, tacrolimus inhibited dephosphorylation of NCC. Together, these results suggest that tacrolimus causes hypertension predominantly by inhibiting calcineurin directly in cells expressing NCC, indicating thiazide diuretics may be particularly effective for lowering BP in tacrolimus-treated patients with hypertension.",
author = "Lazelle, {Rebecca A.} and Belinda McCully and Terker, {Andrew S.} and Nina Himmerkus and Blankenstein, {Katharina I.} and Kerim Mutig and Markus Bleich and Sebastian Bachmann and Chao-Ling Yang and David Ellison",
year = "2016",
month = "5",
day = "1",
doi = "10.1681/ASN.2015040466",
language = "English (US)",
volume = "27",
pages = "1456--1464",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "5",

}

TY - JOUR

T1 - Renal deletion of 12 kDa FK506-binding protein attenuates tacrolimus-induced hypertension

AU - Lazelle, Rebecca A.

AU - McCully, Belinda

AU - Terker, Andrew S.

AU - Himmerkus, Nina

AU - Blankenstein, Katharina I.

AU - Mutig, Kerim

AU - Bleich, Markus

AU - Bachmann, Sebastian

AU - Yang, Chao-Ling

AU - Ellison, David

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Tacrolimus is a widely used immunosuppressive drug that inhibits the phosphatase calcineurin when bound to the 12 kDa FK506-binding protein (FKBP12). When this binding occurs in T cells, it leads to immunosuppression. Tacrolimus also causes side effects, however, such as hypertension and hyperkalemia. Previously, we reported that tacrolimus stimulates the renal thiazide-sensitive sodium chloride cotransporter (NCC), which is necessary for the development of hypertension. However, it was unclear if tacrolimus-induced hypertension resulted from tacrolimus effects in renal epithelial cells directly or in extrarenal tissues, and whether inhibition of calcineurin was required. To address these questions, we developed a mouse model in which FKBP12 could be deleted along the nephron. FKBP12 disruption alone did not cause phenotypic effects. When treated with tacrolimus, however, BP and the renal abundance of phosphorylated NCC were lower in mice lacking FKBP12 along the nephron than in control mice. Mice lacking FKBP12 along the nephron also maintained a normal relationship between plasma potassium levels and the abundance of phosphorylated NCC with tacrolimus treatment. In cultured cells, tacrolimus inhibited dephosphorylation of NCC. Together, these results suggest that tacrolimus causes hypertension predominantly by inhibiting calcineurin directly in cells expressing NCC, indicating thiazide diuretics may be particularly effective for lowering BP in tacrolimus-treated patients with hypertension.

AB - Tacrolimus is a widely used immunosuppressive drug that inhibits the phosphatase calcineurin when bound to the 12 kDa FK506-binding protein (FKBP12). When this binding occurs in T cells, it leads to immunosuppression. Tacrolimus also causes side effects, however, such as hypertension and hyperkalemia. Previously, we reported that tacrolimus stimulates the renal thiazide-sensitive sodium chloride cotransporter (NCC), which is necessary for the development of hypertension. However, it was unclear if tacrolimus-induced hypertension resulted from tacrolimus effects in renal epithelial cells directly or in extrarenal tissues, and whether inhibition of calcineurin was required. To address these questions, we developed a mouse model in which FKBP12 could be deleted along the nephron. FKBP12 disruption alone did not cause phenotypic effects. When treated with tacrolimus, however, BP and the renal abundance of phosphorylated NCC were lower in mice lacking FKBP12 along the nephron than in control mice. Mice lacking FKBP12 along the nephron also maintained a normal relationship between plasma potassium levels and the abundance of phosphorylated NCC with tacrolimus treatment. In cultured cells, tacrolimus inhibited dephosphorylation of NCC. Together, these results suggest that tacrolimus causes hypertension predominantly by inhibiting calcineurin directly in cells expressing NCC, indicating thiazide diuretics may be particularly effective for lowering BP in tacrolimus-treated patients with hypertension.

UR - http://www.scopus.com/inward/record.url?scp=84984663308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984663308&partnerID=8YFLogxK

U2 - 10.1681/ASN.2015040466

DO - 10.1681/ASN.2015040466

M3 - Article

C2 - 26432904

AN - SCOPUS:84984663308

VL - 27

SP - 1456

EP - 1464

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 5

ER -